Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
1(25%)
Results Posted
100%(1 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_3
2
50%
Ph phase_2
2
50%

Phase Distribution

0

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(1)
Terminated(1)

Detailed Status

Not yet recruiting1
Terminated1
Recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (50.0%)
Phase 32 (50.0%)

Trials by Status

not_yet_recruiting125%
terminated125%
recruiting125%
completed125%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_2

Statin Effect on Arrhythmogenic Cardiomyopathy Disease Progression (SEARCH)

NCT06922994
not_yet_recruitingphase_2

Investigating Measurable PRO Acuity Trial (IMPACT) is a Multi-Center Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Maraviroc and Atorvastatin to Improve Neurocognitive and Physical Function of Subjects With Long COVID-19/Post-Acute Sequelae of COVID-19 (PASC).

NCT06974084
terminatedphase_3

Effect of Platelet Inhibition and / or Lipid Lowering in Non-ACS-patients With Positive Troponin

NCT03820466
completedphase_3

Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)

NCT00065806

Clinical Trials (4)

Showing 4 of 4 trials
NCT06922994Phase 2

Statin Effect on Arrhythmogenic Cardiomyopathy Disease Progression (SEARCH)

Recruiting
NCT06974084Phase 2

Investigating Measurable PRO Acuity Trial (IMPACT) is a Multi-Center Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Maraviroc and Atorvastatin to Improve Neurocognitive and Physical Function of Subjects With Long COVID-19/Post-Acute Sequelae of COVID-19 (PASC).

Not Yet Recruiting
NCT03820466Phase 3

Effect of Platelet Inhibition and / or Lipid Lowering in Non-ACS-patients With Positive Troponin

Terminated
NCT00065806Phase 3

Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4